HCA Healthcare leads health systems in Q3 revenue, earnings upticks

An abstract image of a hospital hallway

HCA Healthcare saw a $1.2 billion or 11% jump in its third-quarter revenue, the largest spike among publicly traded health systems reported in the most recent quarterly financial filings.

Officials at the Nashville-based health system giant largely credited the latest upticks to volume growth across its book of business, including the strongest same facilities volume the health system has seen over the last 17 quarters, said HCA's CEO Sam Hazen in a call with investors last month. On a same facilities basis, revenue grew by approximately $700 million or 6.3%, he said.

Inpatient admissions grew 3.2% while equivalent admissions grew 4.2%; emergency room visits grew by 4.1%. Inpatient surgeries grew 2.2%, and outpatient surgeries grew by 2.6%.

Featured Webinar

Reducing barriers to patient care: A cross-industry collaboration

Optum will bring together cross-industry experts to share a case study detailing how an employer, provider, payer and pharmaceutical company worked together to address migraines, a hard-to-diagnose condition. Learn how this team started with a model to risk stratify, predict undiagnosed, misdiagnosed and mismanaged members and how those analytics were used to enrich engagement for treatment and diagnosis optimization.

RELATED: HCA Healthcare's share price up after Q3 revenue, earnings beat expectations

"We had broad-based volume growth across most service categories and it was balanced across our markets with growth in 13 or 14 domestic divisions," Hazen said. The health system reported profits of $612 million on revenues of $12.7 billion in the third quarter ending Sept. 30.

Suggested Articles

A New Jersey medical office has filed suit against Cigna, alleging that the insurer failed to pay for diagnostic testing and treatment for COVID-19.

CMS issued new guidance Friday to help states implement the new interoperability policies in Medicaid and CHIP programs.

GoodRx has released its latest list of the most expensive drugs in America, with orphan drugs and therapies for rare conditions topping the ranking.